• Home
  • About Us

Idiopathic Pulmonary Fibrosis

Jeremy Feldman, MD

  • What is Idiopathic Pulmonary Fibrosis?
    • Idiopathic Pulmonary Fibrosis Definition
    • Symptoms of Idiopathic Pulmonary Fibrosis
    • Causes of Idiopathic Pulmonary Fibrosis
    • Who Gets Idiopathic Pulmonary Fibrosis
    • Gastro-Esophageal Reflux (GER) and Idiopathic Pulmonary Fibrosis
    • Interstitial Lung Disease vs. Idiopathic Pulmonary Fibrosis
    • Is Pulmonary Fibrosis Hereditary?
    • Research, Life Expectancy and Prognosis for Idiopathic Pulmonary Fibrosis
  • Diagnosing & Monitoring PF
    • Monitoring Progress of IPF
    • Idiopathic Pulmonary Fibrosis Diagnosis
    • Chest X-rays Used in IPF
    • CPET used in IPF
    • HRCT Scans Used to Evaluate IPF
    • Lung Biopsy To Diagnose IPF
    • Pulmonary Function Tests (PFTS)
    • Six Minute Walk Test To Monitor IPF
    • Stages of Idiopathic Pulmonary Fibrosis
    • Complications of Idiopathic Pulmonary Fibrosis
  • PF Treatment Options
    • Esbriet (pirfenidone) Used to Treat IPF
    • OFEV (nintedanib) Used to Treat IPF
    • Pulmonary Rehab for IPF Patients
    • Lung Transplantation for Pulmonary Fibrosis
    • Oxygen Used to Treat IPF
      • Update on Oxygen Use
    • Clinical Trials in Idiopathic Pulmonary Fibrosis
    • IPF & Leg Swelling
    • Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
    • IPF Exacerbation
  • PF Advocacy & News
  • FAQ’s
    • Respiratory failure, NSIP, diet
    • Leg swelling, lung biopsy, side effects & pets
    • FAQ’s Enzyme Therapy, Progression of IPF & Oxygen
    • FAQ: Diarrhea, Fibrosis Reversal, IPF Symptoms
    • FAQ: Oxygen Flow, Anesthesia & Genetics
    • FAQ: Contagious Cough? Stem Cells, Familial IPF, Flying
    • FAQ: GERD, Fatigue & Environmental Exposure
    • FAQ: How to Travel to Your Doctor’s Office with Oxygen
    • FAQ: Lung Biopsy with Pulmonary Fibrosis
    • FAQ’s: Alcohol, Clinical Trials, Pulmonary Function Testing
    • FAQs: Emphysema, Exercise & Lung Biopsy

New Drugs Moving Forward for IPF

July 18, 2022 By Dr. Jeremy Feldman

BI 1015550

The past few months have brought very exciting news for IPF patients.  A novel drug being developed by Boehringer Ingelheim (BI 1015550) showed positive results in a phase 2 study.  This new medication blocks the phosphodiesterase 4B receptor.  Blockade of this receptor has shown promise in animal models by causing reduced inflammation and inhibiting fibrosis.  The study which was published in the New England Journal of Medicine enrolled 147 patients with IPF.  Patients were allowed to be on background approved antifibrotic therapy (OFEV or Esbriet).  Patients received either the study drug at 18mg twice daily or placebo.  After 12 weeks, the impact on their lung function (force vital capacity) was measured.  Among patients who were not receiving background antifibrotic therapy, after 12 weeks on study drug, their forced vital capacity had only fallen by 5.7 ml.  In contrast, patients receiving placebo had an average decline of 81.7ml over the same time period.  This is a very significant difference showing the beneficial effects of this study medication on preserving lung function.  Among patients who were receiving approved antifibrotic therapy, the active therapy arm showed a 2.7ml decline in forced vital capacity whereas the placebo group had a 62ml decline.  The drug was well tolerated with the most common side effect being diarrhea. 

For the better part of the last decade, we have only had two options to treat IPF (OVEF and Esbriet).  With this positive result, a phase 3 study will evaluate the medications efficacy in a larger population and hopefully deliver a new medication to add to our arsenal.

PLN-74809

On July 10, 2022, Pliant Therapeutics reported preliminary results of their phase 2 INTEGRIS-IPF trial with their novel compound.  PLN-74809 is a small molecule that binds to and inhibits signaling at two integrin (cell-cell signaling receptors).  67 patients were randomized to receive either placebo, 40, 80 or 160mg of the study drug.  A majority of patients were on background antifibrotic therapy (OFEV or Esbriet).  The primary efficacy endpoint was change in lung function (forced vital capacity) over 12 weeks.  The actively treated patients had less loss of lung function over the 12 weeks of the study (placebo group declined by 74ml compared to the actively treated patients who declined 15ml).  While we await the full publication of the results, we are excited about the prospects of another treatment to help IPF patients. 

Tyvaso

United Therapeutics is currently enrolling a phase 3 study of their already approved therapy Tyvaso in IPF patients.  In 2021, the INCREASE trial suggested a possible benefit in slowing the progression of IPF.  Whereas BI 1015550 and PLN-74809 are experimental therapies, Tyvaso is already widely used in the treatment of pulmonary arterial hypertension and in pulmonary hypertension complicating interstitial lung disease.   

Filed Under: IPF Treatment

Featured Blog Posts

FAQ: Lung Biopsy with Pulmonary Fibrosis

sleep

Sleep Tips for Living with IPF

PF vs IPF

Non-Idiopathic Pulmonary Fibrosis

Recent Posts

  • New Drugs Moving Forward for IPF
  • FAQs: Emphysema, Exercise & Lung Biopsy
  • FAQ’s: Alcohol, Clinical Trials, Pulmonary Function Testing

Search by Keyword (Examples: GERD, Coughing, Traveling, etc.)

Search by Category

Popular Articles

IPF patient with doctor

Idiopathic Pulmonary Fibrosis Treatment Options

What is IPF?

  • What is Idiopathic Pulmonary Fibrosis?
    • Symptoms of Idiopathic Pulmonary Fibrosis
    • Causes of Idiopathic Pulmonary Fibrosis
    • Who Gets Idiopathic Pulmonary Fibrosis
    • Gastro-Esophageal Reflux (GER) and IPF
    • Interstitial Lung Disease vs. Idiopathic Pulmonary Fibrosis
    • Is Pulmonary Fibrosis Hereditary?
    • Research, Life Expectancy & Prognosis for Pulmonary Fibrosis

Diagnosing IPF

  • Idiopathic Pulmonary Fibrosis Diagnosis
    • Chest X-rays Used in IPF
    • CPET used in IPF
    • HRCT Scans Used to Evaluate IPF
    • Lung Biopsy To Diagnose IPF
    • Pulmonary Function Tests (PFTS)
    • Six Minute Walk Test To Monitor IPF
    • Stages of Idiopathic Pulmonary Fibrosis
    • Complications of Idiopathic Pulmonary Fibrosis

Treating IPF

  • Pulmonary Fibrosis Treatment Options
    • Esbriet (pirfenidone) Used to Treat IPF
    • OFEV (nintedanib) Used to Treat IPF
    • Pulmonary Rehab for IPF Patients
    • Lung Transplantation for Pulmonary Fibrosis
    • Oxygen Used to Treat IPF
    • Clinical Trials in Idiopathic Pulmonary Fibrosis
    • IPF & Leg Swelling
    • Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
    • IPF Exacerbation

Disclaimer